FDA Accepts Inovio’s BLA for INO-3107 Review
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inovio Pharmaceuticals ( (INO) ) has provided an announcement.
On December 29, 2025, INOVIO announced that the U.S. Food and Drug Administration accepted for review its Biologics License Application for INO-3107, an investigational DNA medicine intended to treat adults with recurrent respiratory papillomatosis, a rare HPV-driven disease currently managed primarily through repeated surgeries. The application, filed under the accelerated approval pathway and granted a standard review with an October 30, 2026 PDUFA target decision date and no planned advisory committee meeting, is supported by Phase 1/2 data showing substantial reductions in surgery frequency and durable clinical benefit, but the FDA has flagged whether INOVIO has provided sufficient justification for accelerated approval, prompting the company to seek further discussions with regulators as it pursues a non-surgical, first-of-its-kind therapeutic option in a niche but significantly underserved market.
The most recent analyst rating on (INO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.
Spark’s Take on INO Stock
According to Spark, TipRanks’ AI Analyst, INO is a Neutral.
Inovio Pharmaceuticals’ overall stock score reflects significant financial challenges, including persistent losses and negative cash flows, which weigh heavily on the score. Technical analysis indicates a bearish trend, further impacting the score. While the earnings call provided some positive developments in clinical trials and cost management, financial constraints and valuation concerns remain significant risks.
To see Spark’s full report on INO stock, click here.
More about Inovio Pharmaceuticals
INOVIO is a Nasdaq-listed biotechnology company specializing in the development and commercialization of DNA medicines aimed at treating and preventing HPV-related diseases, cancer and infectious diseases, using proprietary DNA plasmid technology delivered via its CELLECTRA medical devices.
Average Trading Volume: 1,279,102
Technical Sentiment Signal: Sell
Current Market Cap: $157.3M
For an in-depth examination of INO stock, go to TipRanks’ Overview page.
